Cargando…
Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impact on health services; hundreds of thousands of healthcare workers (HCWs) have died from coronavirus disease 2019 (COVID-19). The introduction of the BNT162b2 mRNA vaccine in Italy provided recipients...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879462/ https://www.ncbi.nlm.nih.gov/pubmed/35214600 http://dx.doi.org/10.3390/vaccines10020141 |
_version_ | 1784658897250811904 |
---|---|
author | Coppeta, Luca Ferrari, Cristiana Somma, Giuseppina Mazza, Andrea D’Ancona, Umberto Marcuccilli, Fabbio Grelli, Sandro Aurilio, Marco Trabucco Pietroiusti, Antonio Magrini, Andrea Rizza, Stefano |
author_facet | Coppeta, Luca Ferrari, Cristiana Somma, Giuseppina Mazza, Andrea D’Ancona, Umberto Marcuccilli, Fabbio Grelli, Sandro Aurilio, Marco Trabucco Pietroiusti, Antonio Magrini, Andrea Rizza, Stefano |
author_sort | Coppeta, Luca |
collection | PubMed |
description | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impact on health services; hundreds of thousands of healthcare workers (HCWs) have died from coronavirus disease 2019 (COVID-19). The introduction of the BNT162b2 mRNA vaccine in Italy provided recipients with significant protection against COVID-19 within one to two weeks after the administration of the second of the two recommended doses. While the vaccine induces a robust T cell response, the protective role of factors and pathways other than those related to memory B cell responses to specific SARS-CoV-2 antigens remains unclear. This retrospective study aimed to evaluate the determinants of serological protection in a group of vaccinated HCWs (n = 793) by evaluating circulating levels of antiviral spike receptor-binding domain (S-RBD) antibodies during the nine-month period following vaccination. We found that 99.5% of the HCWs who received the two doses of the BNT162b2 vaccine developed protective antibodies that were maintained at detectable levels for as long as 250 days after the second dose of the vaccine. Multivariate analysis was performed on anti-S-RBD titers in a subgroup of participants (n = 173) that were evaluated twice during this period. The results of this analysis reveal that the antibody titer observed at the second time point was significantly related to the magnitude of the primary response, the time that had elapsed between the first and the second evaluation, and a previous history of SARS-CoV-2 infection. Of importance is the finding that despite waning antibody titers following vaccination, none of the study participants contracted severe COVID-19 during the observational period. |
format | Online Article Text |
id | pubmed-8879462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88794622022-02-26 Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine Coppeta, Luca Ferrari, Cristiana Somma, Giuseppina Mazza, Andrea D’Ancona, Umberto Marcuccilli, Fabbio Grelli, Sandro Aurilio, Marco Trabucco Pietroiusti, Antonio Magrini, Andrea Rizza, Stefano Vaccines (Basel) Article The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impact on health services; hundreds of thousands of healthcare workers (HCWs) have died from coronavirus disease 2019 (COVID-19). The introduction of the BNT162b2 mRNA vaccine in Italy provided recipients with significant protection against COVID-19 within one to two weeks after the administration of the second of the two recommended doses. While the vaccine induces a robust T cell response, the protective role of factors and pathways other than those related to memory B cell responses to specific SARS-CoV-2 antigens remains unclear. This retrospective study aimed to evaluate the determinants of serological protection in a group of vaccinated HCWs (n = 793) by evaluating circulating levels of antiviral spike receptor-binding domain (S-RBD) antibodies during the nine-month period following vaccination. We found that 99.5% of the HCWs who received the two doses of the BNT162b2 vaccine developed protective antibodies that were maintained at detectable levels for as long as 250 days after the second dose of the vaccine. Multivariate analysis was performed on anti-S-RBD titers in a subgroup of participants (n = 173) that were evaluated twice during this period. The results of this analysis reveal that the antibody titer observed at the second time point was significantly related to the magnitude of the primary response, the time that had elapsed between the first and the second evaluation, and a previous history of SARS-CoV-2 infection. Of importance is the finding that despite waning antibody titers following vaccination, none of the study participants contracted severe COVID-19 during the observational period. MDPI 2022-01-18 /pmc/articles/PMC8879462/ /pubmed/35214600 http://dx.doi.org/10.3390/vaccines10020141 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Coppeta, Luca Ferrari, Cristiana Somma, Giuseppina Mazza, Andrea D’Ancona, Umberto Marcuccilli, Fabbio Grelli, Sandro Aurilio, Marco Trabucco Pietroiusti, Antonio Magrini, Andrea Rizza, Stefano Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title | Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title_full | Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title_fullStr | Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title_full_unstemmed | Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title_short | Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine |
title_sort | reduced titers of circulating anti-sars-cov-2 antibodies and risk of covid-19 infection in healthcare workers during the nine months after immunization with the bnt162b2 mrna vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879462/ https://www.ncbi.nlm.nih.gov/pubmed/35214600 http://dx.doi.org/10.3390/vaccines10020141 |
work_keys_str_mv | AT coppetaluca reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT ferraricristiana reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT sommagiuseppina reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT mazzaandrea reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT danconaumberto reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT marcuccillifabbio reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT grellisandro reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT auriliomarcotrabucco reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT pietroiustiantonio reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT magriniandrea reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine AT rizzastefano reducedtitersofcirculatingantisarscov2antibodiesandriskofcovid19infectioninhealthcareworkersduringtheninemonthsafterimmunizationwiththebnt162b2mrnavaccine |